AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.
What happened
FDA inspected AseptiKits' North Salt Lake, UT facility from November 11, 2025, through December 3, 2025, and found it manufactures and markets PALA YourTears models 8, 12, 14, ALAdrop, SyrilKit, and VitrALA devices. FDA says the firm lacked an approved premarket approval application or investigational device exemption and did not submit a 510(k) notification. FDA also reviewed the company website and found claims that its devices were 510(k) approved and met FDA requirements, which FDA says are false because the devices were not cleared or approved.
What FDA found
FDA says the company sold devices without the required FDA premarket approval or investigational device exemption.
section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)FDA says the company did not notify FDA before commercially distributing the devices, as required by a 510(k) premarket notification.
section 502(o) of the Act, 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)FDA says the pharmacy compounding system exemption the company relied on does not cover the syringes, filters, and bags that make up these kits.
21 CFR 880.5440(b); FDA special controls guidanceFDA says website statements that the devices were 510(k) approved and met FDA requirements are false and misleading.
section 502(a) of the Act, 21 U.S.C. § 352(a)
What FDA wants
FDA asks the company to immediately stop activities that cause misbranding or adulteration and to respond in writing within 15 business days with the steps taken, corrective actions, and a plan to prevent recurrence.
Who should pay attention
- clinics and pharmacies that use sterile-preparation kits
- distributors or purchasers of convenience kits
- makers of syringes, filters, and closed-system transfer devices
This is a summary. Read the original letter on fda.gov.